Merck的癌症药物Keytruda 以一种新的快速注射形式显示出类似的效果。 Merck's cancer drug Keytruda shows similar effectiveness in a new quick injectable form.

在治疗转移性非小细胞肺癌的第三阶段试验中,与目前的静脉注射版本相比,Keytruda在一种新的亚皮注射形式中表现出类似的效果。 Merck's cancer drug Keytruda showed similar effectiveness in a new subcutaneous injection form compared to its current intravenous version in a Phase 3 trial for treating metastatic non-small cell lung cancer. 与30分钟的IV注射相比,注射版只需几分钟就可管理,它可以改善病人的方便性,帮助Merck在2028年药品专利到期时保持市场份额。 The injectable version, which takes only a few minutes to administer compared to the 30-minute IV infusion, could improve patient convenience and help Merck maintain its market share when the drug's patent expires in 2028. 有关结果将在一次医疗会议上介绍,并与监管者分享。 The results will be presented at a medical meeting and shared with regulators.